GBR 830
Immunology (Undisclosed)
Key Facts
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals has evolved from its 1977 founding into a diversified, global pharmaceutical enterprise with a strategic focus on innovation and accessibility. Under the leadership of Chairman & Managing Director Glenn Saldanha, the company has built significant capabilities in R&D, biologics, and complex generics, supported by a robust pipeline of 25+ candidates and a global commercial footprint. Its strategy centers on advancing a focused pipeline in respiratory, dermatology, and oncology through its biotech arm Ichnos Glenmark Innovation (IGI), while simultaneously scaling its generics and branded formulations business across emerging and developed markets.
View full company profile